Dermapharm Holding SE
DMPHF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $346 | $272 | $302 | $291 |
| % Growth | 27.2% | -10% | 4% | – |
| Cost of Goods Sold | $220 | $88 | $103 | $97 |
| Gross Profit | $126 | $184 | $199 | $193 |
| % Margin | 36.4% | 67.7% | 65.9% | 66.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $55 | $0 | $75 | $79 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$5 | $140 | $64 | $66 |
| Operating Expenses | $50 | $140 | $139 | $145 |
| Operating Income | $76 | $44 | $60 | $48 |
| % Margin | 22% | 16.3% | 19.8% | 16.5% |
| Other Income/Exp. Net | -$11 | -$12 | -$10 | -$13 |
| Pre-Tax Income | $65 | $33 | $50 | $35 |
| Tax Expense | $16 | $12 | $16 | $16 |
| Net Income | $48 | $21 | $33 | $21 |
| % Margin | 14% | 7.7% | 11% | 7.1% |
| EPS | 0.9 | 0.39 | 0.62 | 0.38 |
| % Growth | 130.8% | -37.1% | 63.2% | – |
| EPS Diluted | 0.9 | 0.39 | 0.62 | 0.38 |
| Weighted Avg Shares Out | 54 | 54 | 54 | 54 |
| Weighted Avg Shares Out Dil | 54 | 54 | 54 | 54 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6 | $1 | $2 | -$3 |
| Interest Expense | $17 | $13 | $13 | $12 |
| Depreciation & Amortization | $25 | $20 | $20 | $26 |
| EBITDA | $107 | $66 | $83 | $72 |
| % Margin | 30.8% | 24.3% | 27.3% | 24.9% |